Association of Serum hs-CRP and TNF-α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine (REFORM) Study.

This study explored the role of inflammatory markers in predicting migraine treatment success. Researchers focused on two markers: high-sensitivity C-reactive protein and tumor necrosis factor-alpha. They studied adults with episodic or chronic migraines receiving erenumab. Participants self-administered 140 mg of erenumab every four weeks for 24 weeks. Their serum was collected at the start, after 24 weeks, and 24 weeks post-treatment. Out of 679 participants, 623 had serum analyzed, and 541 had sufficient data. Among these, 282 individuals, or 52%, responded to treatment. Neither high-sensitivity C-reactive protein nor tumor necrosis factor-alpha predicted treatment response. Interestingly, TNF-α levels increased by 3% from baseline to Week 24. However, no differences were observed between responders and non-responders. The findings suggest that common inflammatory markers do not effectively reflect treatment responses, emphasizing the need for targeted biomarkers in migraine therapy. Clinical relevance: This research indicates that common inflammatory markers do not predict migraine treatment success, suggesting a need for more specific biomarkers to enhance personalized treatments.